Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
Saved in:
| Title: | Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER). |
|---|---|
| Authors: | Spring LM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Scarpetti L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Medford AJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Niemierko A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Comander A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Mulvey T; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Schnipper L; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Isakoff SJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Moy B; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Wander SA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Shin J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Ephrem Z; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Laposta AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Denault E; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Abraham E; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Calistro G; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Kalashnikova E; Natera Inc., Austin, TX, USA., Rodriguez A; Natera Inc., Austin, TX, USA., Liu MC; Natera Inc., Austin, TX, USA., Aleshin A; Natera Inc., Austin, TX, USA., Peppercorn J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Ellisen LW; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. abardia@mednet.ucla.edu.; University of California Los Angeles, Los Angeles, USA. abardia@mednet.ucla.edu. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2025 Jan 07; Vol. 11 (1), pp. 2. Date of Electronic Publication: 2025 Jan 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2374-4677 |
|---|---|
| DOI: | 10.1038/s41523-024-00708-5 |
